Primary chronic cold agglutinin disease is a rare hemolytic disease mediated by monoclonal IGHV4-34-encoded cold agglutinins with a predominant specificity for the blood group antigen I. The bone marrow of 54 patients was studied to better type the underlying In conclusion, cold agglutinin-associated lymphoproliferative disease displays homogeneous histological and immunophenotypic features. The absence of plasmacytoid cells, the presence of plasma cells predominantly outside the nodular lymphoid infiltrates, IGHV4-34 restriction and absence of MYD88 L265P mutation strongly suggests that cold agglutinin-associated lymphoproliferative disease is a distinct entity that is different from lymphoplasmacytic lymphoma. 
Introduction
Primary chronic cold agglutinin disease (CAD) accounts for about 15 % of all cases of autoimmune hemolytic anemia. [1] [2] [3] [4] [5] The incidence has been estimated to 1/10 6 pr. year. 6, 7 Anemia results from binding of monoclonal cold agglutinins, most often IgM with κ light chains, to the I antigen on the erythrocyte surface. Bound immunoglobulins cause red blood cell agglutination and complement activation, leading to phagocytosis of complement-coated red blood cells by the reticulo-endothelial system. 4, 8 About 50% of patients become transfusion dependent. The diagnosis of CAD requires a cold agglutinin titer of ≥ 64, a positive polyspecific as well as a C3d complement protein monospecific direct antiglobulin test. 5 The agglutinin titer varies greatly among patients with values as low as 64 to over 500 000. 9 However, the thermal amplitude, defined as the highest temperature at which the antibody binds to red blood cells, is more directly associated with clinical hemolysis than the titer is. 2, 9 Also, the ratio of IgM antibodies that occur as pentamers or hexamers, the latter of which activate complement more easily, determines the severity of the anemia. 10, 11 The immunoglobulin heavy chain of anti-I/i agglutinins is typically encoded by the IGHV4-34 gene segment. The latter is required for binding to I/i antigen on red blood cells. 12 More specifically, the IGHV4-34 framework region 1 (FR1) is mainly responsible for I/i-antigen binding. 13 CAD has previously been associated with underlying B-cell lymphoproliferative disease in up to 75% of the patients with lymphoplasmacytic lymphoma being the most common diagnosis. 6 The demonstration of underlying B-cell lymphoproliferative disease provided the rationale for treatment with rituximab, either as monotherapy or, with better response, in combination with fludarabine therapy.
14, 15 We reviewed morphological and immunophenotypic findings in bone marrow biopsies and aspirates of 54 patients with CAD to critically reappraise the underlying lymphoproliferative disease. To further characterize the cell of origin we analyzed somatic hypermutations of the rearranged immunoglobulin heavy chain gene as well as the BCL6
gene. Additionally, we screened for the MYD88 L265P mutation, known to be highly associated with lymphoplasmacytic lymphoma. 16 ,17
Methods

Patients
Fifty-four patients with clinically well-documented primary CAD diagnosed in the time period between 1995 and 2012 were studied. There were 36 women and 18 men with an age range of 40-92 (median 73) years. All patients had a clinical history of CAD with a variable degree of anemia, a positive C3d-specific direct antiglobulin test and a cold agglutinin titer in excess of 64. Monoclonal IgM had been detected in serum of all patients by agarose electrophoresis and immunofixation. None of the patients had lymphadenopathy or splenomegaly. Clinical follow-up ranged from 3 to 152 months, with a median follow-up of 72 months.
The study was approved by the institutional and regional ethical committees.
Biopsy materials
Archival hematoxylin and eosin-stained sections of bone marrow trephine biopsies from the 54 patients, obtained at diagnosis, were reviewed. Fourteen biopsies were fixed in 4% formaldehyde, 18 in Bplus fixative and 22 in B5 fixative. In addition, part of the diagnostic trephine biopsy of eight patients had been snap-frozen in liquid nitrogen. Two of the patients had undergone splenectomy in an attempt to reduce hemolysis. Hematoxylin and eosin-stained archival sections of formalin-fixed splenic tissue of these patients were reviewed.
Immunohistochemistry
Immunohistochemical analysis was extended or repeated whenever archival sections
were not available or of bad quality. The primary antibodies and the method used for immunohistochemical analysis of the bone marrow trephine biopsies are described in the supplementary methods.
Flow cytometry
Flow cytometry was performed on samples of 25 patients, including a total of 46 bone marrow and 10 paired peripheral blood samples, anticoagulated with heparin and EDTA, respectively. On samples analyzed before 2011, a four-color analysis 18 and from 2011 on, an eight-color analysis 19 was performed with antibody combinations as described in the supplementary methods.
Immunoglobulin heavy chain gene sequencing, BCL6 and MYD88 mutation analyses
DNA was extracted from frozen bone marrow trephine samples, obtained from eight patients, using the EZ1 tissue kit (Qiagen, Hilden, Germany) and from formaldehyde-fixed paraffin embedded-tissue sections from another 9 patients using the QIAamp DNA FFPE tissue kit (Qiagen). Immunoglobulin heavy chain gene analysis and BCL6 intron 1 mutation analysis was only performed on DNA from frozen tissue samples whereas MYD88 mutation analysis, requiring less intact DNA, was performed on frozen and formaldehyde-fixed tissue samples.
BCL6 intron 1 was amplified using three sets of overlapping PCR primers covering nucleotides 24 to 790 in GenBank sequence AF191831. The primer pairs and PCR conditions are described in the supplementary methods. PCR products were sequenced and analyzed using the BLAST database.
The MYD88 L265P mutation (NM_002468) was analyzed using PCR and a SNaPshot multiplex kit (Applied Biosystems). PCR primers and conditions are described in the supplementary method section. A series of 47 fixed bone marrow trephine biopsies of patients with well-documented lymphoplasmacytic lymphoma were used for control purposes.
Results
Patient follow-up
Eighteen patients are alive as of December 31 2012, without relevant co-morbidity, whereas 12 patients are dead. Twenty four patients were eventually treated at other hospitals and no clinical follow-up information is available. None of the patients were diagnosed with extra-medullary lymphoma or developed extra-medullary lymphoma in the course of their disease. Of the 12 patients who died, 3 died with malignant disease (melanoma, ovarian cancer and acute lymphoblastic leukemia, respectively), one patient died with sepsis whereas eight patients died of unknown cause.
Bone marrow pathology
Lymphoid infiltration consisting of nodular B cell aggregates was seen in the marrow of 40 patients. In contrast, 14 patients showed only few and scattered B cells. In the former patients, lymphoid infiltration varied between 5% and 80% of the intertrabecular surface, with a median of 10%. Infiltration was nodular (Fig. 1A-1D ) and consisted of small-sized cells with round to slightly oval nuclei without discernable chromatin pattern ( Fig. 1E and 1F ). The cells showed a small amount of clear cytoplasm. A few scattered histiocytes were admixed with the lymphoid cells. Mature plasma cells were seen surrounding the lymphoid aggregates but were invariably also seen throughout the marrow between the nodular lymphoid aggregates ( Fig. 1G and 1H ). Of interest, only few plasma cells were seen within the nodular lymphoid aggregates (Fig. 1G ). Plasma cells were not abundant and represented less than 5%
(range 2-10) of nucleated cells in the marrow. Of note, features associated with lymphoplasmacytic lymphoma such as paratrabecular growth, fibrosis, lymphoplasmacytoid cell morphology or an increased number of mast cells surrounding the lymphoid aggregates were not seen (Suppl. Fig. 1 ).
To investigate whether a correlation existed between the number of lymphoid aggregates in the bone marrow and hemoglobin concentration, Spearman rank order correlation coefficient (r s ) was calculated. The r s was -0.24, indicating only a very weak negative correlation between the extent of marrow lymphoid infiltration and hemoglobin concentration (Suppl. Table 1 ).
Spleen histology
Review of the records revealed only a partial description of the splenectomy specimens obtained in two patients. The spleen of one patient measured 13 x 11 x 7 cm, but no weight was recorded. The spleen of the second patient weighed 540 grams without a further description of the specimen in the record. Upon review, the histology showed a similar morphology. The red pulp was histologically unremarkable. Scattered plasma cells were noted, but these were not exceptionally numerous. Of note, no abnormal lymphoid infiltration was noted (Fig 2A) . The white pulp was hypoplastic and showed periarteriolar sheets and marginal zones with small lymphoid cells (Fig 2A and 2B ). Lymphoid follicles were absent.
Immunophenotypic analysis
The lymphoid cells within the lymphoid aggregates in the bone marrow trephine biopsies were mainly B cells with few scattered T cells in-between (Fig 3A and 3B ). These Plasma cells seen in the red pulp of the spleen in two of the patients expressed predominantly, but not exclusively, IgM and IgK ( Fig 2C and Fig 2D) . Marginal zone cells in the white pulp showed no obvious restricted immunoglobulin light chain expression ( Fig 2C and Fig 2D) . Infiltrating T-cells were mainly CD4 positive ( Fig 3I and Fig 3J) . The MYD88 L265P mutation analysis was performed on DNA from the eight cases with frozen as well as nine cases with only formalin-fixed paraffin embedded trephine biopsies that showed more than 5% lymphoid infiltration. None of the samples showed the MYD88 L265P mutation. By contrast, MYD88 L265P mutation was demonstrated in fixed and paraffin-embedded bone marrow trephine biopsies in 45 out of 47 cases with lymphoplasmacytic lymphoma.
Immunoglobulin heavy chain gene analysis
Discussion
The 54 patients in the study fulfilled the clinical criteria for primary CAD. However, the histological and immunophenotypic as well as genetic features of CAD differ from those associated with lymphoplasmacytic lymphoma (Table 2) 23, 24 Furthermore, the marker CD27 is strongly positive in CAD-associated lymphoproliferative disease but has been variably reported to be positive in lymphoplasmacytic lymphoma. 25, 26 By contrast, CD25 is mostly positive in lymphoplasmacytic lymphoma complicated by Waldenström disease, while this marker is only variably expressed in CAD. 26 Lymphoplasmacytic lymphoma mostly uses IGVH3 family genes and shows >5% somatic hypermutation, whereas the mutation rate in CAD-associated lymphoproliferative disease is lower. 16, 27, 28 Importantly, the MYD88 L265P mutation, present in over 90% of lymphoplasmacytic lymphoma, has not been demonstrated in any of the CAD samples that were tested in our series. 16, 17 Furthermore, the bone marrow disease in CAD patients is not typical of that seen in other small cell variants of B-cell non-Hodgkin lymphomas such as follicular lymphoma, chronic lymphocytic leukemia and mantle cell lymphoma because cytological and immunophenotypic characteristics typical of these lymphomas are lacking. 22 This is not surprising since the thermal amplitude of the secreted IgM has previously been shown to be the most important factor determining severity of anemia. 2, 9 In addition, the amount of hexameric versus pentameric IgM produced by CAD-associated lymphoproliferative disease might also determine severity of anemia. 10 Hexameric IgM lacks J chain and is highly complement activating and results therefore in increased red blood cell lysis. Of interest, no abnormal bone marrow infiltration with B cells was detected in the biopsy of 14/54 patients, despite a clinically established diagnosis of CAD and a monoclonal B cell population proven by flow cytometry in the four patients analyzed. Sampling error or minimal bone marrow disease with secretion of highly lytic antibodies might explain this finding.
Waldenström macroglobulinemia is a clinical entity defined by lymphoplasmacytic lymphoma in the bone marrow and monoclonal IgM in serum. 29 Therefore, many CAD patients have previously been classified as having Waldenström macroglobulinemia. 30 Based on the findings presented in the current study, patients with CAD should not be included with true Waldenström macroglobulinemia. A minority of CAD patients show no obvious bone marrow lymphoproliferative disease. We suggest that the latter patients be diagnosed
clinically as having an IgM-related disorder. The latter is defined as a clinical condition mediated by monoclonal IgM without evidence of lymphoma. 31 However, patients without obvious bone marrow disease probably represent one end of the spectrum seen in CAD rather than having a distinct disease 5 . This is supported by our previous findings that the extent of bone marrow involvement does not correlate with response to B-cell directed therapy.
14,15
Monoclonal IGHV4-34 gene rearrangement is a well-described finding in CAD and is also detected in our patients. 12 The framework region 1 (FR1) of the IGHV4-34 gene segment determines anti-I/i specificity. 32 Especially, amino acid residues 7, 23-25 determine this specificity and are conserved in CAD despite that most rearranged immunoglobulin genes show somatic hypermutation. 33, 34 The latter has also been shown in our cases. In addition to FR1, crystallography has indicated that the exposed C-terminal flanking region but not the antigen-binding pocket site of CDR3 is also important for binding to I/i-antigen. 35 The antigen-binding pocket site of the antibody may therefore bind to another additional antigen.
The latter may be heterogeneous in CAD as indicated by variable CDR3 regions without obvious sequence motifs, except for the absence of positively charged amino acids, as shown in our study and in other studies. 12, 20 Of interest, two patients in our series show identical and In conclusion, by studying the bone marrow of a large series of patients with primary CAD, we have provided arguments for an underlying primary bone marrow B-cell lymphoproliferative disease with unique pathologic and genetic features that distinguish the disease from well-characterized B-cell lymphoma types. Of interest, trisomy of chromosome 3q11-q29 is a common feature of the four cases hitherto described 41, 42 , although all cases show additional unique changes. These recurrent genetic changes support the notion that CAD-associated lymphoproliferative disease is a distinct entity. A more extensive genetic analysis is needed to clarify the molecular basis of the disease. analyzed the data and wrote the paper. All authors discussed the findings, reviewed the manuscript critically and approved the submitted version.
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Immunoglobulin heavy chain gene sequencing, BCL6 and MYD88 mutation analyses:
The immunoglobulin heavy chain variable regions were amplified using the IgH Somatic Hypermutation Assay kit according to the instructions of the manufacturer (InVivoScribe Technologies, France) and products were separated using the ABI 3100 Genetic Analyzer (Applied Biosystems, Weiterstadt, Germany). PCR products were sequenced from both ends with the Big Dye Terminator v 1.1 sequencing kit (Applied Biosystems) using the ABI 3100
Genetic Analyzer (Applied Biosystems). All sequences proved to be IGHV4-34 sequences.
However a number of sequences were of suboptimal quality for detailed analysis due to background immunoglobulin sequences resulting from the consensus PCR technique.
Therefore, some of the samples were re-amplified using IGHV4-34 specific primers (5'-CAG GTG CAG CTA CAG CAG T-3' or 5'-CAG GTG CAG CTA CAA CAG T-3') and
AmpliTaq Gold polymerase (Applied Biosystems) and sequencing was repeated. The final nucleotide sequences obtained were analyzed using BLAST (www.ncbi.nlm.nih.gov) and IMGT/V-QVEST (www.imgt.org) databases.
BCL6 intron 1 analysis:
The primer pairs were: 5'-CCG CCG CTG CTC ATG ATC ATT ATT T-3' and 5'-ACC AAA ACA ACA CAA GGG AGG GTG G-3'; 5'-GGC CGG TTT GGG GAG GCT TTT-3'
and 5'-GAG CGG GCA GCC TCC CTT TT-3'; 5'-CCC TTC CCC TGT CCT TCT GGG T-3' and 5'-GGC TCT CTT CCA TCG GCC TCG-3', respectively. PCR amplification using AmpliTaq Gold polymerase (Applied Biosystems) consisted of an initial denaturation step at 95°C for 7 min., followed by 35 cycles at 95°C for 30 sec, 58°C or 60°C for 30 sec and 72°C
for 45 sec and a final extension step at 72 °C for 8 min.
MYD88 L265P mutation analysis:
PCR was carried out using Phusion hot start DNA polymerase (Thermo Fisher Scientific) 
